Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,836
archived clinical trials in
Leukemia

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Monter Cancer Center of the North Shore-LIJ Health System
mi
from
Lake Success, NY
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Monter Cancer Center of the North Shore-LIJ Health System
mi
from
Lake Success, NY
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
CCOP - North Shore University Hospital
mi
from
Manhasset, NY
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
CCOP - North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Mount Sinai Hospital
mi
from
New York, NY
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Leo W. Jenkins Cancer Center at ECU Medical School
mi
from
Greenville, NC
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Leo W. Jenkins Cancer Center at ECU Medical School
mi
from
Greenville, NC
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Pardee Memorial Hospital
mi
from
Hendersonville, NC
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Pardee Memorial Hospital
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Kinston Medical Specialists
mi
from
Kinston, NC
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Kinston Medical Specialists
mi
from
Kinston, NC
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington, D.C.,
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Community Cancer Center
mi
from
Normal, IL
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Butterworth Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Butterworth Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Mountainview Medical
mi
from
Berlin Corners, VT
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Mountainview Medical
mi
from
Berlin Corners, VT
Click here to add this to my saved trials
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/7/2017
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/7/2017
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Phase I Study of Vidaza and Velcade (Bortezomib) in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/21/2017
Ohio State University Medical Center
mi
from
Columbus, OH
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Phase I Study of Vidaza and Velcade (Bortezomib) in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/21/2017
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Status: Enrolling
Updated:  8/30/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Status: Enrolling
Updated: 8/30/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Status: Enrolling
Updated:  8/30/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Status: Enrolling
Updated: 8/30/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
New York Medical College
mi
from
Valhalla, NY
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Methodist Children's Hospital of South Texas
mi
from
San Antonio, TX
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Methodist Children's Hospital of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Oncology Group
mi
from
Arcadia, CA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Oncology Group
mi
from
Arcadia, CA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital Colorado
mi
from
Aurora, CO
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
All Children's Hospital
mi
from
Saint Petersburg, FL
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Memorial Hospital
mi
from
Chicago, IL
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Indiana University Cancer Center
mi
from
Indianapolis, IN
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital-Main Campus
mi
from
New Orleans, LA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital-Main Campus
mi
from
New Orleans, LA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Johns Hopkins University
mi
from
Baltimore, MD
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials